Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
66.59 USD | -2.65% | -3.92% | -17.80% |
01/07 | HOOKIPA Pharma Reports First Patient Dosed in HIV Treatment Study | MT |
01/07 | HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.80% | 8.52TCr | |
+54.07% | 82TCr | |
+38.59% | 63TCr | |
-7.05% | 35TCr | |
+15.44% | 32TCr | |
+5.72% | 29TCr | |
+13.40% | 24TCr | |
+0.61% | 22TCr | |
+13.24% | 22TCr | |
+7.42% | 17TCr |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90